Research

Research Activity & Clinical Trials

2011 -A phase 2 maximal use systemic exposure study evaluating the safety and efficacy of Calcipotriol 50mcg/g plus Betamethasone O.Smg/g (as Dipropionate) gel applied once daily in subjects with extensive psoriasis vulgaris on the scalp and non-scalp regions of the body (trunk and/or limbs) U7

2011 - A phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the efficacy and Safety of2 Oral Doses ofCP-690, 550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis.

2010 -A phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in subjects with Moderate to Severe Plaque Psoriasis.

2010 - A phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study ofTwo Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis.

2009 -Calcipotriol plus hydrocortisone in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and on the intertriginous areas. A phase 3 study comparing an ointment containing calcipotriol 25 meg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with hydrocortisone 10 mg/g ointment, both applied once daily in the treatment of psoriasis vulgaris on the face and intertriginous areas. An international, multi-centre, prospective, randomised, double­ blind, active-controlled, 2-arm, parallel group, 8-week clinical study

2009- A phase 2B, multicenter, treatment-arm blind, safety and efficacy 28-week extension study for Apremilast (CC-10004) in subjects who completed the treatment phase of the core study CC-10004-PSOR-005

2008-2011 A study of dose optimization of infliximab in the treatment of moderate to severe plaque psoriasis

2008-2009 LEO 19123 cream in the treatment of psoriasis vulgaris. A phase 2 study, comparing the efficacy and safety of LEO 19123 (calcipotriol 50 mcglg plus LEO 80122 0.6 mg/g) cream with Dovonex® cream (calcipotriol 50 mcg/g) and with the LEO 19123 cream vehicle alone in the treatment of psoriasis vulgaris. A multi-centre, prospective, randomised, active and vehicle controlled, investigator blinded, right/left comparison in 2 groups treated for 4 weeks

2008-Effect of calcipotriol plus hydrocortisone ointment on the HPA axis and calcium metabolism in patients with psoriasis vulgaris on the face and on the intertriginous areas. A phase 2 study evaluating the safety and efficacy of calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ointment applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas. An international, multi-centre, prospective, open, non-controlled, 8-week clinical study

2008-A 10-year, post-marketing, observational, registry of HUMIRA® (adalimumab) in patients with chronic plaque psoriasis (Ps)

2008-A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, efficacy and safety study of Apremilast (CC-I 0004) in subjects with moderate-to-severe plaque-type psoriasis (Core Study)

2008 -A phase III, multicenter, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two dosing regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis

2008- Real-world assessment of long-term infliximab therapy for psoriasis

2008 -A phase IV Remicade® observational study in psoriasis: health economics, co-morbidities and therapeutic use

2006- A multicenter, open label, continuation study in moderate to severe chronic plaque psoriasis subjects who completed a preceding psoriasis clinical study with adalimumab

2006-Canadian assessment of patient outcomes and effectivenes of Enbrel in psoriasis (Sub­ Investigator)

2006-A phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis (Phoenix 1)

2003 -2005 A phase II, randomized, double-blind, placebo-controlled, parallel study of single and multiple dose regimens with subcutaneous CNTO 1275 (human monoclonal antibody to IL-12) in subjects with moderate to severe psoriasis

2003-2005 A phase M, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of intliximab induction therapy followed by multiple regimens of maintenance intliximab therapy in patients with plaque-type psoriasis

2003 -2005 A randomized, placebo-controlled, double-blind, multicenter study examining the efficacy and safety of weekly intramuscular administration of 15 mg alefacept over 12 weeks in a population of psoriasis patients for whom conventional treatments is ineffective or inappropriate

2003 -2005 An open-label long-term extension study to assess the safety of etanercept in the treatment of psoriasis in adult subjects (Sub-Investigator)

2003 - A multicenter international observational study of the long-term safety of XXXX; RESULTS: XXXX safety under long-term study

2003- A multicenter, randomized, double-blind, placebo controlled phase study of subcutaneously administered Raptiva in the treatment of patients with moderate to severe psoriasis

2002 -2004 A phase M, multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of intliximab induction and maintenance therapy in patients with moderate to severe plaque psoriasis

2002-2004 A multicenter, randomized, double-blind trial of anti-TNF alfa chimeric monoclonal antibody (infliximab) for the treatment of patients with psoriatic arthritis (Sub-Investigator)

2002 -2004 An open-label, multicenter study to evaluate the safety and tolerability of intramuscular administration of alefacept (LFA-3/IgG1 fusion protein) in subjects with chronic plaque psoriasis who have completed studies C99-717 or C99-712

2002- Efficacy, safety and tolerability of Elide (pimecrolimus) cream in the treatment of anal eczema: multicenter, placebo-controlled investigator initiated trial

2002-A randomized, double-blind, placebo-controlled, parallel group study to assess the safety and efficacy of three dose levels of rosiglitazone maleate in the treatment of chronic plaque psoriasis (Sub-Investigator)

2002- A double-blind, placebo controlled, phase II randomized study to assess, in combination with high compression therapy, the safety and potential efficacy of homologous human plasma fibroncctin applied topically in a calcium-alginate sponge-like disk (DERMALINK. delivery system, compared to a calcium sponge-like disk without fibronectin (the placebo), in the treatment of chronic venous ulcers of the lower limbs (Sub-Investigator)

2002-A 6-month open-label, multi-national, effectiveness, and safety study of Elidel (pimccrolimus) cream, 1% in subjects with atopic dermatitis (Sub-Investigator)

2002-Open study comparing the efficacy of Diane 35 in combination with Epilaser versus Epilaser alone in the treatment of Hirsutism (Sub-Investigator)

2002-12-week post-treatment follow-up period, in patients with plaque psoriasis who have no change or an increase in their overall lesional assessment (OLA) after 12 weeks of treatment in a study of oral tazarotene 4.5 mg versus placebo (Sub-Investigator)

2002-A randomized, double-blind, placebo-controlled, exploratory pharmacogenomic study of recombinant human interleukin eleven (rhiL-11) in patients with active psoriasis (Sub-Investigator)

2002- An open-label, multicenter study to evaluate the efficacy and safety of 1.0 mg/kg subcutaneously administered efalizumab followed by efalizumab taper in adults with plaque psoriasis previously enrolled in study ADC2390g (Sub-Investigator)

2002 -A phase lllb, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of 1.0 mg/kg subcutaneous administered efalizumab in adults with moderate to severe plaque psoriasis

2002-A multicentre, single arm prospective, open label study to assess the safety of Elidel (SDZ ASM 981-pimecrolimus) cream 1% in patients with atopic dermatitis (Sub-Investigator)